Repurposing of gallium-based drugs for antibacterial therapy

BioFactors

Volumn 40, Issue 3, 2014, Pages 303-312

  Bonchi, Carlo ^a   Imperi, Francesco ^b   Minandri, Fabrizia ^a   Visca, Paolo ^a   Frangipani, Emanuela ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti infectives; Bacteria; Chemotherapy; Drug repositioning; Ganite; Iron metabolism

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; GALLIUM; GALLIUM NITRATE; IRON; OXIDOREDUCTASE; ANTIINFECTIVE AGENT; ORGANOMETALLIC COMPOUND;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL METABOLISM; BIOCHEMISTRY; BURKHOLDERIA CEPACIA COMPLEX; CANCER CELL; CELL GROWTH; CHEMOTHERAPY; EUKARYOTIC CELL; IN VITRO STUDY; IRON METABOLISM; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROKARYOTIC CELL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS PSEUDINTERMEDIUS; ANIMAL; BACTERIA; BACTERIAL INFECTIONS; CHEMISTRY; DRUG EFFECTS; DRUG REPOSITIONING; HUMAN; METABOLISM;

ACINETOBACTER BAUMANNII; ANIMALIA; BACTERIA (MICROORGANISMS); EUKARYOTA; MYCOBACTERIUM TUBERCULOSIS; PROKARYOTA; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG REPOSITIONING; DRUG RESISTANCE, BACTERIAL; GALLIUM; HUMANS; ORGANOMETALLIC COMPOUNDS;

EID: 84902553986     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1159     Document Type: Review

References (115)

1. Lecoq de Boisbaudran, P.E. (1875) Caractères chimiques et spectroscopiques d'un nouveau metal, le gallium, decouvert dans une blende de la mine de Pierrefitte, vallee d'Argeles (Pyrenees). Bull. Soc. Chim. 24, 370-371.
2. Dudley, H.C. and Levine M.D. (1949) Studies of the toxic action of gallium. J. Pharmacol. Exp. Ther. 95, 487-493.
3. Dudley, H.C., Maddox, G.E., and La Rue, H.C. (1949) Studies of the metabolism of gallium. J. Pharmacol. Exp. Ther. 96, 135-138.
4. Dudley, H.C., Henry, K.E., and Lindsley, B.F. (1950) Studies of the toxic action of gallium. J. Pharmacol. Exp. Ther. 98, 409-417.
5. Edwards, C.L., and Hayes, R.L. (1969) Tumor scanning with 67Ga citrate. J. Nucl. Med. 10, 103-105.
6. Lavender, J.P., Lowe, J., Barker, J.R., Burn, J.I., and Chaudhri, M.A. (1971) Gallium 67 citrate scanning in neoplastic and inflammatory lesions. Br. J. Radiol. 44, 361-366.
7. Littenberg, R.L., Taketa, R.M., Alazraki, N.P., Halpern, S.E., and Ashburn, W.L. (1973) Gallium-67 for localization of septic lesions. Ann. Intern. Med. 79, 403-406.
8. Hopkins, G.B., and Mende, C.W. (1975) Gallium-67 and subphrenic abscesses-is delayed scintigraphy necessary? J. Nucl. Med. 16, 609-611.
9. Thadepalli, H., Rambhatla, K., Mishkin, F.S., Khurana, M.M., and Niden, A.H. (1977) Correlation of microbiologic findings and 67-gallium scans in patients with pulmonary infections. Chest 72, 442-448.
10. Levaditi, C., Bardet, J., Tchakirian, A., and Vaisman, A. (1931) Le gallium, propriétés thérapeutiques dans la syphilis et les trypanosomiases expérimentales. C. R. Hebd. Seances Acad. Sci. Ser. D. Sci. Nat. 192, 1142-1143.
11. Shannon, R.D. (1976) Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystallogr. 32, 751-767.
12. Smith, R.M. and Martell, A.E. (1976) Critical Stability Constants, vol 4. Plenum Press, New York.
13. Hancock, R.D. and Marsicano, F. (1980) Parametric correlation of formation constants in aqueous solution: 2-Ligands with large donor atoms. Inorg. Chem. 19, 2709-2714.
14. Pearson, R.G. (1988) Absolute electronegativity and hardness: application to inorganic chemistry. Inorg. Chem. 27, 734-740.
15. Huheey, J.E., Keiter, E.A., and Keiter, R.L. (1993) Inorganic Chemistry: Principles of Structure and Reactivity, 4th edn. Harper Collins, New York.
16. Hegge, F.N., Mahler, D.J., and Larson, S.M. (1977) The incorporation of Ga-67 into the ferritin fraction of rabbit hepatocytes in vivo. J. Nucl. Med. 18, 937-939.
17. Hoffer, P.B., Huberty, J., and Khayam-Bashi, H. (1977) The association of Ga-67 and lactoferrin. J. Nucl. Med. 18, 713-717.
18. Vallabhajosula, S.R., Harwig, J.F., Siemsen, J.K., and Wolf, W. (1980) Radiogallium localization in tumors: blood binding and transport and the role of transferrin. J. Nucl. Med. 21, 650-656.
19. Harris, W.R. and Pecoraro, V.L. (1983) Thermodynamic binding constants for gallium transferrin. Biochemistry 22, 292-299.
20. Harris, W.R. (1986) Thermodynamics of gallium complexation by human lactoferrin. Biochemistry 25, 803-808.
21. Gray-Owen, S.D. and Schryvers, A.B. (1996) Bacterial transferrin and lactoferrin receptors. Trends Microbiol. 4, 185-191.
22. Clausen, J., Edeling, C.J., and Fogh, J. (1974) 67Ga binding to human serum proteins and tumor components. Cancer Res. 34, 1931-1937.
23. McGregor, S.J. and Brock, J.H. (1992) Effect of pH and citrate on binding of iron and gallium by transferrin in serum. Clin. Chem. 38, 1883-1885.
24. Masson, P.L., Heremans, J.F., and Dive, C. (1966) An iron-binding protein common to many external secretions. Clin. Chim. Acta 14, 735-739.
25. Chitambar, C.R. and Zivkovic, Z. (1987) Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Res. 47, 3929-3934.
26. Gunasekera, S.W., King, L.J., and Lavender, P.J. (1972) The behaviour of tracer gallium-67 towards serum proteins. Clin. Chim. Acta 39, 401-406.
27. Braud, A., Hannauer, M., Mislin, G.L., and Schalk, I.J. (2009) The Pseudomonas aeruginosa pyochelin-iron uptake pathway and its metal specificity. J. Bacteriol. 191, 3517-3525.
28. Braud, A., Hoegy, F., Jezequel, K., Lebeau, T., and Schalk, I.J. (2009) New insights into the metal specificity of the Pseudomonas aeruginosa pyoverdine-iron uptake pathway. Environ. Microbiol. 11, 1079-1091.
29. Logan, K.J., Ng, P.K., Turner . C.J., Schmidt, R.P., Terner, U.K., et al. (1981) Comparative pharmacokinetics of 67Ga and 59Fe in humans. Int. J. Nucl. Med. Biol. 8, 271-276.
30. Chitambar, C.R., Matthaeus, W.G., Antholine, W.E., Graff, K., and O'Brien, W.J. (1988) Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 72, 1930-1936.
31. Hedley, D.W., Tripp, E.H., Slowiaczek, P., and Mann, G.J. (1988) Effect of gallium on DNA synthesis by human T-cell lymphoblasts. Cancer Res. 48, 3014-3018.
32. Berggren, M.M., Burns, L.A., Abraham, R.T., and Powis, G. (1993) Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate. Cancer Res. 53, 1862-1866.
33. Anghileri, L.J., Thuvenot, P., Brunotte, F., Marchal, C., and Robert, J. (1982) Ionic competition and 67Ga in vivo accumulation. Nuklearmedizin 21, 114-116.
34. Waalkes, T.P., Sanders, K., Smith, R.G., and Adamson, R.H. (1974) DNA polymerases of Walker 256 carcinosarcoma. Cancer Res. 34, 385-391.
35. Adamson, R.H., Canellos, G.P., and Sieber, S.M. (1975) Studies on the antitumor activity of gallium nitrate (NSC-15200) and other group IIIa metal salts. Cancer Chemother. Rep. 59, 599-610.
36. Manfait, M. and Collery, P. (1992) Etude in vitro par spectroscopie Raman de la conformation d'un ADN sous l'influence des ions magnésium et gallium. Magnesium Bull. 4, 153-155.
37. Tajmir-Riahi, H.A., Naoui, M., and Ahmad, R. (1992) A comparative study of calf-thymus DNA binding trivalent Al, Ga, Cr and Fe ions in aqueous solution. In Metal Ions in Biology and Medicine, vol. 2. (Anastassopoulou, J., Collery, P., Etienne, J.C., Theophanides, T., et al. eds.). pp. 98-101, John Libbey Eurotext, Paris.
38. Hart, M.M., Smith, C.F., Yancey, S.T., and Adamson, R.H. (1971) Toxicity and antitumor activity of gallium nitrate and periodically related metal salts. J. Natl. Cancer Inst. 47, 1121-1127.
39. Foster, B.J., Clagett-Carr, K., Hoth, D., and Leyland-Jones, B. (1988) Gallium nitrate: the second metal with clinical activity. Cancer Treat. Rep. 70, 1311-1319.
40. Chitambar, C.R. (2004) Gallium nitrate for the treatment of non-Hodgkin's lymphoma. Expert. Opin. Investig. Drugs 13, 531-541.
41. Warrell, R.P., Bockman, R.S., Coonley, C.J., Isaacs, M., and Staszewski, H. (1984) Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J. Clin. Invest. 73, 1487-1490.
42. Verron, E., Bouler, J.M., and Scimeca, J.C. (2012) Gallium as a potential candidate for treatment of osteoporosis. Drug Discov. Today 17, 1127-1132.
43. Whitacre, C., Apseloff, G., Cox, K., Matkovic, V., Jewell, S. et al. (1992). Suppression of experimental autoimmune encephalomyelitis by gallium nitrate. J. Neuroimmunol. 39, 175-181.
44. Huang, E.H., Gabler, D.M., Krecic, M.E., Gerber, N., Ferguson, R.M., et al. (1994) Differential effects of gallium nitrate on T lymphocyte and endothelial cell activation. Transplantation 58, 1216-1222.
45. Hall, S.W., Yeung, K., Benjamin, R.S., Stewart, D., Valdivieso, M. et al., (1979) Kinetics of gallium nitrate, a new anticancer agent. Clin. Pharmacol. Ther. 25, 82-87.
46. Krakoff, I.H., Newman, R.A., and Goldberg, R.S. (1979) Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer 44, 1722-1777.
47. Kelsen, D.P., Alcock, N., Yeh, S., Brown, J., and Young, C. (1980) Pharmacokinetics of gallium nitrate in man. Cancer 46, 2009-2013.
48. Collery, P., Millart, H., Lamiable, D., Vistelle, R., Rinjard, P., et al. (1989) Clinical pharmacology of gallium chloride after oral administration in lung cancer patients. Anticancer Res. 9, 353-356.
49. Bernstein, L.R., Tanner, T., Godfrey, C., and Noll, B. (2000) Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Met. Based Drugs 7, 33-47.
50. Newman, R.A., Brody, A.R., and Krakoff, I.H. (1979) Gallium nitrate (NSC-15200) induced toxicity in the rat: a pharmacologic, histopathologic and microanalytical investigation. Cancer 44, 1728-1740.
51. Collery, P., Millart, H., Pluot, M., and Anghileri, L.J. (1986) Effects of gallium chloride oral administration on transplanted C3HBA mammary adenocarcinoma: Ga, Mg, Ca and Fe concentration and anatomopathological characteristics. Anticancer Res. 6, 1085-1088.
52. Vistelle, R., Collery, P., and Millart, H. (1989) In vivo distribution of gallium in healthy rats after oral administration and interactions with iron, magnesium and calcium. Trace Elem. Med. 6, 27-32.
53. Chitambar, C.R., Purpi, D.P., Woodliff, J., Yang, M., and Wereley, J.P. (2007) Development of gallium compounds for treatment of lymphoma: Gallium maltolate, a novel hydroxypyrone gallium compound induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J. Pharmacol. Exp. Ther. 322, 1228-1236.
54. Bernstein, L.R., van der Hoeven, J.J., and Boer, R.O. (2011) Hepatocellular carcinoma detection by gallium scan and subsequent treatment by gallium maltolate: rationale and case study. Anticancer Agents Med. Chem. 11, 585-590.
55. Collery, P., Domingo, J.L., and Keppler, B.K. (1996) Preclinical toxicology and tissue gallium distribution of a novel antitumour gallium compound: tris(8-quinolinolato)-gallium (III). Anticancer Res. 16, 687-691.
56. Valiahdi, S.M., Heffeter, P., Jakupec, M.A., Marculescu, R., Berger, W. et al. (2009) The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. Melanoma Res. 19, 283-293.
57. Murren, J., Modiano, M., Clairmont, C., Lambert, P., Savaraj, N., et al. (2003) Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin. Cancer Res. 9, 4092-4100.
58. Visca, P. (2004) Iron regulation and siderophore signalling in virulence by Pseudomonas aeruginosa. In Pseudomonas: virulence and gene regulation, vol. II. (Ramos, J.L. ed.). pp. 69-123, Kluwer Academic Publishers, Dordrecht, The Netherlands.
59. Weinberg, E.D. (2009) Iron availability and infection. Biochim. Biophys. Acta 1790, 600-605.
60. Miethke, M., and Marahiel, M.A. (2007) Siderophore-based iron acquisition and pathogen control. Microbiol. Mol. Biol. Rev. 71, 413-451.
61. Wandersman, C. and Delepelaire, P. (2004) Bacterial iron sources: from siderophores to hemophores. Annu. Rev. Microbiol. 58, 611-647.
62. Krewulak, K.D. and Vogel, H.J. (2008) Structural biology of bacterial iron uptake. Biochim. Biophys Acta. 1778, 1781-1804.
63. Cescau, S., Cwerman, H., Létoffé, S., Delepelaire, P., Wandersman, C. et al. (2007) Heme acquisition by hemophores. Biometals 20, 603-613.
64. Cartron, M.L., Maddocks, S., Gillingham, P., Craven, C.J., and Andrews, S.C. (2006) Feo-transport of ferrous iron into bacteria. Biometals 19, 143-157.
65. Takase, H., Nitanai, H., Hoshino, K., and Otani, T. (2000) Requirement of the Pseudomonas aeruginosa tonB gene for high-affinity iron acquisition and infection. Infect. Immun. 68, 4498-4504.
66. Velayudhan, J., Hughes, N.J., McColm, A.A., Bagshaw, J., Clayton, C.L., et al. (2000) Iron acquisition and virulence in Helicobacter pylori: a major role for FeoB, a high-affinity ferrous iron transporter. Mol. Microbiol. 37, 274-286.
67. Brickman, T.J. and Armstrong, S.K. (2007) Impact of alcaligin siderophore utilization on in vivo growth of Bordetella pertussis. Infect. Immun. 75, 5305-5312.
68. Fetherston, J.D., Kirillina, O., Bobrov, A.G., Paulley, J.T., and Perry, R.D. (2010) The yersiniabactin transport system is critical for the pathogenesis of bubonic and pneumonic plague. Infect. Immun. 78, 2045-2052.
69. Miranda-Casoluengo, R., Coulson, G.B., Miranda-Casoluengo, A., Vázquez-Boland, J.A., Hondalus, M.K., et al. (2012) The hydroxamate siderophore rhequichelin is required for virulence of the pathogenic actinomycete Rhodococcus equi. Infect. Immun. 80, 4106-4114.
70. Thomas-Charles, C.A., Zheng, H., Palmer, L.E., Mena, P., Thanassi, D.G., et al. (2013) FeoB-mediated uptake of iron by Francisella tularensis. Infect. Immun. 81, 2828-2837.
71. Wells, R.M., Jones, C.M., Xi, Z., Speer, A., Danilchanka, O., et al. (2013) Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PLoS Pathog. 9, e1003120.
72. Ballouche, M., Cornelis, P., and Baysse, C. (2009) Iron metabolism: a promising target for antibacterial strategies. Recent Pat. Antiinfect. Drug Discov. 4, 190-205.
73. Möllmann, U., Heinisch, L., Bauernfeind, A., Köhler, T., and Ankel-Fuchs, D. (2009) Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals 22, 615-624.
74. Foley, T.L., and Simeonov, A. (2012) Targeting iron assimilation to develop new antibacterials. Expert Opin. Drug Discov. 7, 831-847.
75. Imperi, F., Massai, F., Facchini, M., Frangipani, E., Visaggio, D., et al. (2013) Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. Proc. Natl. Acad. Sci. U.S.A. 110, 7458-7463.
76. Visca, P., Bonchi, C., Minandri, F., Frangipani, E., and Imperi, F. (2013) The dual personality of iron chelators: growth inhibitors or promoters? Antimicrob. Agents Chemother. 57, 2432-2433.
77. Hider, R.C. and Kong, X. (2010) Chemistry and biology of siderophores. Nat. Prod. Rep. 27, 637-657.
78. Poole, K. and McKay, G.A. (2003) Iron acquisition and its control in Pseudomonas aeruginosa: many roads lead to Rome. Front. Biosci. 1, 8:d661-686.
79. Garcia, E.C., Brumbaugh, and A.R., Mobley, H.L. (2011) Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection. Infect. Immun. 79, 1225-1235.
80. Bernstein, L.R. (1998) Mechanisms of therapeutic activity for gallium. Pharmacol. Rev. 50, 665-682.
81. Olakanmi, O., Britigan, B.E., and Schlesinger, L.S. (2000) Gallium disrupts iron metabolism of mycobacteria residing within human macrophages. Infect. Immun. 68, 5619-5627.
82. Kaneko, Y., Thoendel, M., Olakanmi, O., Britigan, B.E., and Singh, P.K. (2007) The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J. Clin. Invest. 117, 877-888.
83. Rzhepishevska, O., Ekstrand-Hammarström, B., Popp, M., Björn, E., Bucht, A., et al. (2011) The antibacterial activity of Ga3+ is influenced by ligand complexation as well as the bacterial carbon source. Antimicrob. Agents Chemother. 55, 5568-5580.
84. Antunes, L.C., Imperi, F., Minandri, F., and Visca, P. (2012) In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 56, 5961-5970.
85. de Léséleuc, L., Harris, G., KuoLee, R., and Chen, W. (2012) In vitro and in vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii. Antimicrob. Agents Chemother. 56, 5397-5400.
86. Litwin, C.M. and Calderwood, S.B. (1993) Role of iron in regulation of virulence genes. Clin. Microbiol. Rev. 6, 137-149.
87. Olakanmi, O., Gunn, J.S., Su, S., Soni, S., Hassett, D.J., et al. (2010) Gallium disrupts iron uptake by intracellular and extracellular Francisella strains and exhibits therapeutic efficacy in a murine pulmonary infection model. Antimicrob. Agents Chemother. 54, 244-253.
88. Olakanmi, O., Kesavalu, B., Pasula, R., Abdalla, M.Y., Schlesinger, L.S., et al. (2013) Gallium nitrate is efficacious in murine models of tuberculosis and inhibits key bacterial fe-dependent enzymes. Antimicrob. Agents Chemother. 57, 6074-6080.
89. García-Contreras, R., Lira-Silva, E., Jasso-Chávez, R., Hernández-González, I.L., Maeda, T., et al. (2013) Isolation and characterization of gallium resistant Pseudomonas aeruginosa mutants Int. J. Med. Microbiol., 303, 574-578.
90. Kelson, A.B., Carnevali, M., and Truong-Le, V. (2013) Gallium-based anti-infectives: targeting microbial iron-uptake mechanisms. Curr. Opin. Pharmacol. 13, 707-771.
91. Minandri, F., Bonchi, C., Frangipani, E., Imperi, F., and Visca, P. (2014) Promises and failures of gallium as an antibacterial agent. Future Microbiol. 9.
92. Mahren S, Schnell H, and Braun V. (2005) Occurrence and regulation of the ferric citrate transport system in Escherichia coli B, Klebsiella pneumoniae, Enterobacter aerogenes, and Photorhabdus luminescens. Arch. Microbiol. 184, 175-186.
93. Marshall, B., Stintzi, A., Gilmour, C., Meyer, J.M., and Poole, K. (2009) Citrate-mediated iron uptake in Pseudomonas aeruginosa: involvement of the citrate-inducible FecA receptor and the FeoB ferrous iron transporter. Microbiology 155, 305-315.
94. Banin, E., Lozinski, A., Brady, K.M., Berenshtein, E., Butterfield, P.W., et al. (2008) The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent. Proc. Natl. Acad. Sci. U.S.A. 105, 16761-16766.
95. Döring, G., Flume, P., Heijerman, H., Elborn, J.S.; and Consensus Study Group. (2012) Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 11, 461-479.
96. García-Contreras, R., Pérez-Eretza, B., Lira-Silva, E., Jasso-Chávez, R., Coria-Jiménez, R., et al. Gallium induces the production of virulence factors in Pseudomonas aeruginosa. Pathog. Dis., in press. doi: 10.1111/2049-632X.12105.
97. Høiby, N., Ciofu, O., Johansen, H.K., Song, Z.J., Moser, C., et al. (2011) The clinical impact of bacterial biofilms. Int. J. Oral Sci. 3, 55-65.
98. Yang . L., Liu . Y., Wu . H., Song . Z., Høiby . N., et al. (2012) Combating biofilms. FEMS Immunol. Med. Microbiol. 65, 146-157.
99. Fothergill, J.L., Winstanley, C., and James, C.E. (2012) Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev. Anti. Infect. Ther. 10, 219-235.
100. Peeters, E., Nelis, H.J., and Coenye, T. (2008) Resistance of planktonic and biofilm-grown Burkholderia cepacia complex isolates to the transition metal gallium. J. Antimicrob. Chemother. 61, 1062-1065.
101. Lynch, J.P. (2009) Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion. Semin. Respir. Crit. Care. Med. 30, 596-610.
102. Goss, C.H., Hornick, D.B., Aitken, M.L., Anderson, G., and Caldwell, E. (2012) Phase 1 pharmacokinetic and safety study of intravenous GaniteTM (Gallium nitrate) in CF. Pediatric Pulmunol. 47, 303.
103. World Health Organization. (2013) Global Tuberculosis Control 2013. World Health Organization, Geneva.
104. Baldoni, D., Steinhuber, A., Zimmerli, W., and Trampuz, A. (2010) In vitro activity of gallium maltolate against Staphylococci in logarithmic, stationary, and biofilm growth phases: comparison of conventional and calorimetric susceptibility testing methods. Antimicrob. Agents Chemother. 54, 157-163.
105. Arnold, C.E., Bordin, A., Lawhon, S.D., Libal, M.C., Bernstein, L. R., et al. (2012) Antimicrobial activity of gallium maltolate against Staphylococcus aureus and methicillin-resistant S. aureus and Staphylococcus pseudintermedius: An in vitro study. Vet. Microbiol. 155, 389-394.
106. Liapikou, A. and Torres A. (2013) Emerging drugs on methicillin-resistant Staphylococcus aureus. Expert Opin. Emerg Drugs. 18, 291-305.
107. DeLeon, K., Balldin, F., Watters, C., Hamood, A., Griswold, J., et al. (2009) Gallium maltolate treatment eradicates Pseudomonas aeruginosa infection in thermally injured mice. Antimicrob. Agents Chemother. 53, 1331-1337.
108. Lambert, M.L., Suetens, C., Savey, A., Palomar, M., Hiesmayr, M., et al. (2011) Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect. Dis. 11, 30-38.
109. Begum, K., Kim, H.S., Kumar, V., Stojiljkovic, I., and Wataya, Y. (2003) In vitro antimalarial activity of metalloporphyrins against Plasmodium falciparum. Parasitol. Res. 90, 221-224.
110. Lessa, J.A., Parrilha, G.L., and Belardo, H. (2012) Gallium complexes as new promising metallodrug candidates. Inorg. Chim. Acta 393, 53-63.
111. Fecteau, M.E., Fyock, T.L., McAdams, S.C., Boston, R.C., Whitlock, R.H., et al. (2011) Evaluation of the in vitro activity of gallium nitrate against Mycobacterium avium subsp paratuberculosis. Am. J. Vet. Res. 72, 1243-1246.
112. Fecteau, M.E., Whitlock, R.H., Fyock, T.L., McAdams, S.C., Boston, R.C., et al. (2011b) Antimicrobial activity of gallium nitrate against Mycobacterium avium subsp. paratuberculosis in neonatal calves. J. Vet. Intern. Med. 25, 1152-1155.
113. Novick, S.C., Julian, T.N., Majuru, S., Mangelus, M. Brown, B.D., et al. (2008) Initial phase I clinical and pharmacokinetic assessment of G4544, an oral gallium-containing compound. J. Clin. Oncol. 26, 8592.
114. Martens, R.J., Mealey, K., Cohen, N.D., Harrington, J.R., Chaffin, M.K., et al. (2007) Pharmacokinetics of gallium maltolate after intragastric administration in neonatal foals. Am. J. Vet. Res. 68, 1041-1044.
115. Coleman, M., Kuskie, K., Liu, M., Chaffin, K., Libal, M., et al. (2010) In vitro antimicrobial activity of gallium maltolate against virulent Rhodococcus equi. Vet. Microbiol. 146, 175-178.